Kentucky Bioprocessing (KBP) (owned by British American Tobacco) recently launched a clinical trial to test its seasonal flu vaccine candidate. Working with research site organization Meridian Clinical Research, the sponsor and principal investigator will be targeting 120 volunteers in Omaha, Nebraska. A world leader in using tobacco and other plants to produce pharmaceuticals and other high value products, the company is focused on developing standardized templates to produce highly effective vaccines that target a wide variety of diseases, while meeting stringent regulatory requirements for process and production control. After two years of preliminary work, the company has progressed to the Phase I clinical trial for the investigational influenza vaccine called KBP-V001.
The Investigational Vaccine Candidate
Back in April 2020, TrialSite News introduced Kentucky Bioprocessing (owned by British American Tobacco) and their effort to develop a COVID-19 vaccine. In May, Genetic Engineering & Biotechnology News updated the market that the COVID-19 vaccine was still in preclinical.
Now an investigational influenza vaccine know...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).